Skip header and navigation

59 records – page 1 of 6.

Document Type
Evidence Search Report
Review Code
PH011401-01 ESR
Question Submitted
January 14, 2021
Date Completed
January 15, 2021
Status
3. Completed
Research Team
Public Health
Date: January 15, 2021 Subject(s): Vaccines, Decision Making, Health Planning. Cite As: Mueller, M
Document Type
Evidence Search Report
Review Code
PH011401-01 ESR
Question Submitted
January 14, 2021
Date Completed
January 15, 2021
Status
3. Completed
Research Team
Public Health
Category
Administration
Infection Prevention and Control
Subject
Vaccines
Decision Making
Health Planning
Population
All
Clinical Setting
Primary care
Public Health
Priority Level
Level 1 2-3 days
Cite As
Mueller, M; Howell-Spooner, B. How are other jurisdictions distributing COVID-19 vaccines in non-healthcare worker environments and what is the rationale for those distribution models? 2021 Jan 15; Document no.: PH011401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
PH011401 RR
Question Submitted
January 14, 2021
Date Completed
January 19, 2021
Status
3. Completed
Research Team
Public Health
#ational decision making or organi#ational decision-making or ((organi#ational or administrative
Document Type
Rapid Review
Review Code
PH011401 RR
Question Submitted
January 14, 2021
Date Completed
January 19, 2021
Status
3. Completed
Research Team
Public Health
Key Findings
· Recommended to use existing vaccination structures and delivery services as much as possible for distribution of the COVID-19 vaccines · Important to consider cold-chain requirements when developing distribution plans · Should consider alternate locations for hard-to-reach populations that are easily accessible and familiar · Consider branching out to mobile vaccination (e.g. home visits, door-to-door), pharmacies, workplaces, congregate living facilities, walk-up/drive-through mechanisms for vaccine delivery
Category
Administration
Infection Prevention and Control
Subject
Vaccines
Decision Making
Health Planning
Population
All
Clinical Setting
Primary care
Public Health
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Mueller, M; Howell-Spooner, B. How are other jurisdictions distributing COVID-19 vaccines in non-healthcare worker environments and what is the rationale for those distribution models? 2021 Jan 19; Document no.: PH011401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
CC210301 ESR
Question Submitted
March 30, 2021
Date Completed
March 31, 2021
Status
3. Completed
Research Team
Critical Care
scorecard could be prospectively applied by hospitals seeking a structured approach to decision-making
Document Type
Evidence Search Report
Review Code
CC210301 ESR
Question Submitted
March 30, 2021
Date Completed
March 31, 2021
Status
3. Completed
Research Team
Critical Care
Category
Administration
Clinical Management
Subject
Critical Care
Decision Making
Treatment
Facilities
Population
All
Clinical Setting
ICU
Priority Level
Level 1 2-3 days
Cite As
Young, C; Ellsworth, C. How to deliver remote ICU care for COVID-19 patients to avoid/prevent transfer from smaller communities to tertiary care hospitals. 2021 Mar 31; Document no.: CC210301 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 18 p. (CEST evidence search report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
CC210301 RR
Question Submitted
March 30, 2021
Date Completed
April 6, 2021
Status
3. Completed
Research Team
Critical Care
Document Type
Rapid Review
Review Code
CC210301 RR
Question Submitted
March 30, 2021
Date Completed
April 6, 2021
Status
3. Completed
Research Team
Critical Care
Key Findings
· Tele-ICU services are provided either by existing staff within the network to smaller centers, or outsourced to larger networks or independent firms · The impact of tele-ICU adoption can result in a decrease in ICU mortality as large as 32% · The impact of tele-ICU adoption of length of stay is mixed, with some studies reporting a significant decrease, while others report a small, but statistically insignificant decrease · The degree of impact of tele-ICU adoption is linked to several factors such as yearly admission rates, location (urban vs. rural) and level of authority given to the tele-ICU team leading to increased positive impacts.
Category
Administration
Clinical Management
Subject
Critical Care
Decision Making
Facilities
Treatment
Population
All
Clinical Setting
ICU
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Young, C; Ellsworth, C; Howell-Spooner, B. How to deliver remote ICU care for COVID-19 patients to avoid/prevent transfer from smaller communities to tertiary care hospitals. 2021 Apr 6; Document no.: CC210301 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC081301-01 ESR
Question Submitted
August 12, 2020
Date Completed
August 12, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC081301-01 ESR
Question Submitted
August 12, 2020
Date Completed
August 12, 2020
Status
3. Completed
Research Team
EOC
Category
Diagnostics
Subject
Testing
Public Health
Decision Making
Priority Level
Level 3 completed within 2-3 days
Cite As
Dalidowicz, M. Is pooled testing for COVID-19 equally as reliable as individual testing and what are the optimal pool testing sizes? 2020 Aug 12; Document no.: EOC081301-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 8 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC081301 RR
Question Submitted
August 12, 2020
Date Completed
August 14, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC081301 RR
Question Submitted
August 12, 2020
Date Completed
August 14, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Pool testing for COVID-19 can be equal to individual testing in terms of sensitivity, specificity and positive and negative prediction rates · Pooled testing is optimal for use when disease prevalence is low, as prevalence increases, optimal pool sizes decrease and efficiency is lost · At a prevalence of approximately 1%, optimal pool sizes have been found to be up to 13 · Pools of 5 were found to be equally efficient and could be done using 50% less tests up to a prevalence of 5% · Recommended for use in large scale asymptomatic screening, highest viral load occurs before symptoms so less likely to miss borderline positive in convalescent stage · Not recommended for clinical diagnostic use
Category
Diagnostics
Subject
Testing
Public Health
Decision Making
Priority Level
Level 3 completed within 2-3 days
Cite As
Badea, A; Muhajarine, N; Dalidowicz, M. Is pooled testing for COVID-19 equally as reliable as individual testing and what are the optimal pool testing sizes? 2020 Aug 14; Document no.: EOC081301 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 19 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC220501 ESR
Question Submitted
May 3, 2022
Date Completed
May 4, 2022
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC220501 ESR
Question Submitted
May 3, 2022
Date Completed
May 4, 2022
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Subject
Decision Making
Infection Prevention and Control
Vaccination
Priority Level
Level 1 2-3 days
Cite As
Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 04. Document no.: EOC220501 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC220501 RR Table
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
Document Type
Table
Review Code
EOC220501 RR Table
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Subject
Decision Making
Infection Prevention and Control
Vaccination
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC220501 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC220501 RR
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC220501 RR
Question Submitted
May 3, 2022
Date Completed
May 10, 2022
Status
3. Completed
Research Team
EOC
Key Findings
Recommendations for COVID-19 vaccination timing following monoclonal antibody or convalescent plasma therapy range from a precautionary 90 day deferral, to assessing on a case-by-case basis to no need for deferral
Only published evidence is a sub-study of the larger Bamlanivimab trial where prophylactic administration of Bamlanivimab prior to mRNA COVID-19 vaccination did not affect the immune response regardless of age, risk category or vaccine product used
No evidence currently exists for vaccination timing following the use of antiviral products such as Paxlovid or Remdesivir
Category
Clinical Management
Subject
Decision Making
Infection Prevention and Control
Vaccination
Priority Level
Level 1 2-3 days
Cite As
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 10 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC220301 SBAR
Question Submitted
March 1, 2022
Date Completed
May 2022
Status
3. Completed
Research Team
EOC
motivational interviewing techniques to inform decision-making for COVID-19 vaccination (4) Monica
Document Type
Rapid Review
Review Code
EOC220301 SBAR
Question Submitted
March 1, 2022
Date Completed
May 2022
Status
3. Completed
Research Team
EOC
Notes
This is not a regular rapid review. It was decided to write this SBAR instead.
Category
Healthcare Services
Subject
Vaccines
Vaccination
Public Health
Decision Making
Health Personnel
Infection Prevention and Control
Population
All
Clinical Setting
Community
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Rowein S, Singh S, Habbick M, Mehdiyeva K, Miller L, Gagneur, A, Groot G, Neudorf C, Camillo CA, Tokhmafshan, F, Muhajarine N. Motivational Interviewing for Vaccine Hesitancy. May 2022. Document no.: [12.1]. CoVaRR-Net Public Health, Health Systems, Social Policy Team, c2022.
Related Documents
Documents
Less detail

59 records – page 1 of 6.